KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.

Product information

CAS Number: 170365-25-0

Molecular Weight: 609.16

Formula: C36H37ClN4O3

Chemical Name: 4-({2-[4-(2-chlorophenyl)piperazine-1-carbonyl]-1-[2-(dimethylamino)ethyl]-1H-indol-3-yl}(4-hydroxyphenyl)methyl)phenol

Smiles: CN(C)CCN1C(C(=O)N2CCN(CC2)C2=CC=CC=C2Cl)=C(C(C2C=CC(O)=CC=2)C2C=CC(O)=CC=2)C2C=CC=CC1=2

InChiKey: HESAJCAYRSKRSG-UHFFFAOYSA-N

InChi: InChI=1S/C36H37ClN4O3/c1-38(2)19-24-41-31-9-5-3-7-29(31)34(33(25-11-15-27(42)16-12-25)26-13-17-28(43)18-14-26)35(41)36(44)40-22-20-39(21-23-40)32-10-6-4-8-30(32)37/h3-18,33,42-43H,19-24H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells. KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM ).

In Vivo:

KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production.

Products are for research use only. Not for human use.